T cells are the 'foot soldiers' that fight cancer inside the body. Cancer cells can fight the foot soldiers back by pushing a brake on the T cells that will turn them off. This 'brake' is a molecule ...

Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) is an immunogenic protein receptor that is expressed almost exclusively on CD4+ and CD8+ T cells. It plays a crucial role in the homeostasis of ...

A collaborative team of leaders in the field of cancer immunology from Memorial Sloan Kettering Cancer Center has made a key discovery that advances the understanding of why some patients respond to ...

Alexander I. Sankin comments on some of the ongoing developments in bladder cancer. Researchers should start looking beyond the successful CTLA-4 and PD-L1 agents in bladder cancer, says Alexander I.

Immune checkpoint inhibitors are effective cancer treatments, but molecular determinants of clinical benefit are unknown. Ipilimumab and tremelimumab are antibodies against cytotoxic T-lymphocyte ...

Researchers from La Jolla Institute for Allergy and Immunology and their collaborators from other institutes recently discovered a potential new target for cancer immunotherapy. Led by Dr. Amnon ...

Recent phase III clinical trials have established the superiority of the anti-PD-1 antibodies pembrolizumab and nivolumab over the anti-CTLA-4 antibody ipilimumab in the first-line treatment of ...

The recent article by Tawbi et al. 1 showed superior progression-free survival with the combination of relatlimab (an anti–lymphocyte-activation gene 3 [LAG-3] antibody) and nivolumab over nivolumab ...

Microbiota-reactive T cells trigger colitis in mice harboring the microbiota of wild-caught mice following CTLA-4 blockade, according to a new study that reveals a major mechanism by which anti-CTLA-4 ...

Researchers discovered that an immunotherapy, called anti-CTLA-4, mobilizes microglia against glioblastoma as it causes CD4+ T cell infiltration of the brain. A study led by Salk Institute (CA, USA) ...

SOUTH SAN FRANCISCO, Calif., June 22, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX) today announced that its partner Bristol Myers Squibb presented preclinical data from BMS-986249 ...